# A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

> **NCT03410875** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Hairy Cell Leukemia
- Leukemia
- Leukemia, Hairy Cell

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT03410875
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-09
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410875, "A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03410875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*